Market Newsdesk

SANTA CLARA, Calif., Nov. 16, 2020 /PRNewswire/ — Cloudera, Inc. (NYSE: CLDR), the enterprise data cloud company, announced that it will report its third quarter fiscal year 2021 (ended October 31, 2020) financial results on December 3, 2020 after the close of market, and host a conference call to discuss the results at 1:30 PM Pacific Time (4:30 PM Eastern Time).

Conference Call and Webcast Information

The conference call can be accessed as follows:

• Participant Toll Free Number: +1-833-579-0900
• Participant International Number: +1-778-560-2567
• Conference ID: 2257327

A webcast of the conference call can be accessed from the News & Events section of the Company’s website at https://investors.cloudera.com/events/Events/default.aspx. A replay of the webcast will be available for at least two weeks following completion of the call.   

About Cloudera
At Cloudera, we believe that data can make what is impossible today, possible tomorrow. We empower people to transform complex data into clear and actionable insights. Cloudera delivers an enterprise data cloud for any data, anywhere, from the Edge to AI. Powered by the relentless innovation of the open source community, Cloudera advances digital transformation for the world’s largest enterprises. Learn more at cloudera.com.

Cloudera and associated marks are trademarks or registered trademarks of Cloudera, Inc. All other company and product names may be trademarks of their respective owners.

View original content to download multimedia:http://www.prnewswire.com/news-releases/cloudera-sets-date-to-announce-third-quarter-fiscal-year-2021-results-301173470.html

SOURCE Cloudera, Inc.

Company’s most personalized program ever offers a comprehensive approach to wellness

For more media materials, please visit:

 


https://www.multivu.com/players/English/8815451-ww-international-myww-plus-canada/

OAKVILLE, ON, Nov. 16, 2020 /CNW/ – Today, WW International, Inc. (NASDAQ: WW), has introduced myWW+ which offers a more holistic approach to weight loss and wellness that focuses on food, activity, mindset and sleep – pillars of health which have a measurable impact on success. Building on the massive success of the myWW program and through a deeply enriching, more interactive and personalized app experience, myWW+ offers members a plan that works best for them with new tools designed to make weight loss easier.

In addition to featuring an all new Personal Assessment which will help people pinpoint the changes that will power their personal weight loss success, myWW+ delivers customized content powered by a smart personalization platform that uses machine learning and AI to identify the preferences of each unique member —  the more a member engages with the content and features, the more myWW+ delivers.

“As a human-centric technology company, we know how important it is for people to have a comprehensive app experience that helps them lose weight and get healthier so they can become the best version of themselves,” said Mindy Grossman, WW CEO and President. “Our myWW+ program offers a sought-after holistic wellness solution that is also highly customizable to fit your life, no matter where it takes you.”

One of the newest features with myWW+ is the Weekly Check-in – a personalized, holistic view of your progress within the app. Members can now review how their week went and automatically receive a Progress Report to see the full picture related to food, activity, mindset and sleep.  For the upcoming week, members create an Action Plan by selecting suggested actionable goals or creating their own. Their weekly goal will be displayed to help maintain focus throughout the week. With these new tools that digitize and customize behavioural goal-setting, people will stay engaged and on track to successfully reach their goals.

“With our expertise in behaviour change, we go beyond the basics of education and guidance and offer a personalized, action-oriented approach for our members,” said Gary Foster, PhD, Chief Scientific Officer, WW. “What’s particularly compelling about myWW+ is that we have been able to scale behaviour change like never before by taking science-based principles and translating them into digital tools to make the weight and wellness journey easier for all of our members.”

“Canadian research shows that this unprecedented year has impacted our physical and mental health,” said Kevin O’Brien, General Manager and President of WW Canada. “With myWW+, Canadians now have access to tools, support and community that empower them to put a comprehensive and multi-faceted focus on their wellness.”    

In addition to understanding your progress and setting goals, myWW+ offers even more features focused on key wellness elements to make the weight loss journey easier and more successful, such as:

• Food: New meal planning tools, such as “Meal Planner” and “What’s In Your Fridge” (in beta) to help members customize what they want to eat throughout the week based on their eating preferences, time restrictions and the foods they have on hand.
• Activity: A redesigned activity experience gives members a new way to view and understand daily activity, weekly goals and progress over time. Members can also continue to move in ways they love with on-demand equipment-free workouts through in-app content from partners such as FitOn and Aaptiv. 
• Mindset: WW now provides its science-backed mindset techniques in bite-sized audio sessions via new 5-Minute Coaching. These science-backed techniques are rooted in cognitive behavioural, acceptance-based, and positive psychology sciences and are organized by relevant categories such as Manage Eating, Help for Stress, etc.
• Sleep: WW members can track sleep (manually or synced through a wearable) to get tailored advice and learn practical, science-based strategies to improve sleep habits.

The app still includes popular features, such as food, water and activity trackers, the barcode scanner, and Connect – WW’s members-only digital community. Access to the WW app is included with all subscription-based memberships on the myWW+ program. The program is rooted in WW’s scientifically proven approach to weight loss and nutrition and grounded in the SmartPoints^® system and ZeroPoint™ foods. WW remains a category leader, having been ranked for a decade as #1 “Best for Weight Loss” by health experts in U.S. News & World Report’s Best Diets rankings.  

For more information, please visit www.ww.ca.

About WW International, Inc.
WW – Weight Watchers reimagined – is a global wellness company powered by the world’s leading commercial weight management program. We inspire millions of people to adopt healthy habits for real life. Through our engaging tech-enabled experience and face-to-face group workshops, members follow our livable and sustainable program of healthy eating, physical activity, and a helpful mindset. Leveraging more than five decades of experience in building inspired communities and our deep expertise in behavioral science, we aim to democratize wellness and to deliver wellness for all. To learn more about the WW approach to healthy living, please visit ww.com. For more information about our global business, visit our corporate website at corporate.ww.com. 

SOURCE WW

HONG KONG, Nov. 16, 2020 /PRNewswire/ — CLPS Incorporation (Nasdaq: CLPS) (“CLPS” or “the Company”), today announced that it has won the IT services provider bid for a well-known bank card processing services company in China (“Client”). CLPS, through its Shanghai subsidiary, and the Client have signed the Procurement of IT Services Provider Agreement. Both parties have agreed to cooperate in the development, operation, maintenance, and testing of the bank card issuance core system and peripheral value-added products, as well as in providing consulting and data analysis services.

CLPS has successfully won the bid on its initial cooperation with the Client. For over ten years, CLPS has implemented set of comprehensive credit card system services for a major U.S. bank, large state-owned banks in China, and for a leading international credit card association. In addition, the Company’s extensive experience and its pool of highly qualified IT professionals make it a cut above the other competitors. Moreover, CLPS has been commended by its clients for its capability in providing credit card technology and business services. The cooperation also sets a major achievement in the credit card services business of CLPS, following the establishment of Qinson Credit Card Services Ltd., the Company’s wholly-owned subsidiary focused on credit card services, which gains a strong foothold for business growth going forward.

The Client is a subsidiary of a leading bank card association in China. It offers consulting and data analysis services focused in the credit card business. In addition, it provides card issuance data processing service that covers different types of cards, such as credit card, debit card, prepaid card, and integrated circuit (IC) card for offline transaction. The Client follows the Chinese and international card associations’ compliance standards to ensure a secure, stable, and efficient operational services for more than two hundred card issuers and millions of bank cards in China and globally.

Mr. Henry Li, Chief Operating Officer of CLPS, said, “With years of continuous business development and improvement, we are confident and excited for our credit card services to be offered to our clients, which effectively reflects the Company’s successful implementation of its growth strategy. CLPS consistently adheres to achieving a mutually beneficial cooperation and providing clients with world-class professional IT services.”

About CLPS Incorporation

Headquartered in Hong Kong, CLPS Incorporation (the “Company”) (Nasdaq: CLPS) is a global leading information technology (“IT”), consulting and solutions service provider focusing on the banking, insurance and financial sectors. The Company serves as an IT solutions provider to a growing network of clients in the global financial industry, including large financial institutions in the US, Europe, Australia, Southeast Asia and Hong Kong, and their PRC-based IT centers. The Company maintains 18 delivery and/or research & development centers to serve different customers in various geographic locations. Mainland China centers are located in Shanghai, Beijing, Dalian, Tianjin, Baoding, Chengdu, Guangzhou, Shenzhen, Hangzhou, and Suzhou. The remaining eight global centers are located in Hong Kong SAR, USA, UK, Japan, Singapore, Malaysia, Australia, and India. For further information regarding the Company, please visit: http://ir.clpsglobal.com/, or follow CLPS on Facebook, LinkedIn, and Twitter.

Forward-Looking Statements

Certain of the statements made in this press release are “forward-looking statements” within the meaning and protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to the Company’s beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond the Company’s control, and which may cause the actual results, performance, capital, ownership or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All such statements attributable to us are expressly qualified in their entirety by this cautionary notice, including, without limitation, those risks and uncertainties related to the Company’s financial and operational performance in the second half and full year of fiscal 2020, its expectations of the Company’s future performance, its preliminary outlook and guidance offered in this presentation, as well as the risks and uncertainties described in the Company’s most recently filed SEC reports and filings. Such reports are available upon request from the Company, or from the Securities and Exchange Commission, including through the SEC’s Internet website at http://www.sec.gov. We have no obligation and do not undertake to update, revise or correct any of the forward-looking statements after the date hereof, or after the respective dates on which any such statements otherwise are made.

Contact:    

CLPS Incorporation

Rhon Galicha

Investor Relations Office 
Phone: +86-182-2192-5378
Email: [email protected]

View original content:http://www.prnewswire.com/news-releases/clps-incorporation-wins-bid-for-a-well-known-bank-card-processing-services-company-a-major-achievement-in-credit-card-services-business-301173519.html

SOURCE CLPS

Highlights:

• PBM-113
   intersected 5.00m of 8.35% copper equivalent (CuEq) comprising of 8.08% copper, 0.20 g/t gold, 10.55 g/t silver and 0.13% zinc;
• PBM-113 intersected a second interval of 4.0m of 2.31% CuEq comprising of 2.21% copper, 0.09 g/t gold, 2.28 g/t silver and 0.04% zinc;
• PBM-113 intersected a third interval of 9.06m of 3.72% CuEq comprising of 2.37% copper, 0.70 g/t gold, 7.00 g/t silver and 2.10% zinc;
• Interpretation of new Borehole Pulse Electromagnetic survey suggests mineralization comes within 350m of surface; and
• Two rigs are currently drilling to expand the discovery along strike and to surface.

VANCOUVER, BC, Nov. 16, 2020 /PRNewswire/ – Callinex Mines Inc. (the “Company” or “Callinex”) (TSXV: CNX) (OTC: CLLXF) is pleased to provide results from the ongoing drilling campaign to expand the Rainbow Discovery at the 100% owned Pine Bay Project located in the Flin Flon Mining District of Manitoba (See Figure 1). The Rainbow Discovery has been made on Callinex’s mineral lease, less than 250m from a high-voltage power-line and 550m from a historic shaft with direct road access to processing facilities in Flin Flon, MB (See Figure 2).

Drill hole PBM-113 intersected the following three high-grade intersections 145m away (along strike and above) from the discovery hole PBM-111 (See Figure 3): 

• Orange Zone returned:
• 5.00m of 8.35% copper equivalent (CuEq) comprising of 8.08% copper, 0.20 g/t gold, 10.55 g/t silver and 0.13% zinc including 3.00m of 12.13% copper, 0.27 g/t gold, 15.62 g/t silver and 0.18% zinc; an
• 4.00m of 2.31% CuEq including 2.21% copper, 0.09 g/t gold, 2.28 g/t silver and 0.04% zinc.
• Yellow Zone returned 9.06m of 3.72% CuEq comprising of 2.37% copper, 0.70 g/t gold, 7.00 g/t silver and 2.10% zinc including 3.75m of 4.15% copper, 1.20 g/t gold, 11.87 g/t silver and 4.19% zinc. 

The Rainbow discovery hole, PBM-111, intersected 2.96 metres of 4.43% CuEq comprising of 3.09% copper, 0.75 g/t gold, 13.35 g/t silver, 1.88% zinc (Yellow Zone) and a second interval of 4.31 metres of 4.32% CuEq comprising of 4.12% copper, 0.22 g/t gold, 2.21 g/t silver, 0.06% zinc (Orange Zone) (See News Release Dated September 9, 2020). The mineralization intersected in drill hole PBM-113 intersected significantly wider intervals and higher grades of both base and precious metals.

Drill Hole PBM-112 intersected the Rainbow Horizon 345m vertically above PBM-111 and went over the presumed plunge line when it crossed the Rainbow horizon (Orange Zone). A subsequent Borehole Pulse Electromagnetic survey (“BPEM”) survey completed on PBM-112 confirms this interpretation and suggests the Rainbow Discovery possibly comes within 350m of surface based on the modeled data.

Two additional drill holes, PBM-113-W1 and PBM-114, have been completed with assays pending.  Currently, two rigs are drilling step-out holes as the Company delineates the Rainbow Discovery.  Drill hole PBM-115 is currently being drilled to test ~75m along strike to the north of PBM-113.  Additionally, a second wedge, PBM-113-W2, has been started off PBM-113 to intersect ~60M vertically above PBM-113-W1. The two drill rigs will continue to operate to delineate the Rainbow Discovery until mid-December for a brief holiday break and resume drilling in early January 2021. 

Table 1: Pine Bay Drill Results

Notes(1)(2)(3)(4):

J.J. O’Donnell, P.Geo, a qualified person under National Instrument 43-101, has reviewed and approved the technical information in this news release.

Figure 1: Flin Flon Mining District Region Overview 
Figure 2: Plan View of the Rainbow Discovery at the Pine Bay Project
Figure 3: Pine Bay Long Section Looking West with 2020 Drilling

QA / QC Protocols
Individual samples were labeled, placed in plastic sample bags, and sealed. Groups of samples were then placed in security sealed bags and shipped directly to SGS lab in Vancouver, BC for analysis. Samples were weighed then crushed to 75% passing 2mm and pulverized to 85% passing 75 microns in order to produce a 250g pulverized split. 35 elements including copper, zinc, lead and silver assays were determined by Aqua Regia digestion with a combination of ICP-MS and ICP-AES finish, with over limits rerun using an ore grade analysis (two acid digest ICP-AES).  Gold was analyzed by fire assay. Specific gravity (sg) measured for each sample using the pycnometer and water and air method. QA/QC included the insertion and continual monitoring of numerous standards, blanks, and duplicates

About Callinex Mines Inc.


Callinex Mines Inc. (TSXV: CNX) (OTC: CLLXF) is advancing its portfolio of base and precious metals rich deposits located in established Canadian mining jurisdictions. The portfolio is highlighted by the rapidly expanding Rainbow Discovery at its Pine Bay Project located near existing infrastructure in the Flin Flon Mining District. Additionally, Callinex has emerging near-surface silver discoveries at its Nash Creek Project located in the Bathurst Mining District of New Brunswick. A 2018 PEA on the Company’s Bathurst projects outlined a mine plan that generates a strong economic return with a pre-tax IRR of 34.1% (25.2% post-tax) and NPV8% of $230 million ($128 million post-tax).

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Some statements in this news release contain forward-looking information. These statements include, but are not limited to, statements with respect to future expenditures. These statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements. Such factors include, among others, the ability to complete the proposed drill program and the timing and amount of expenditures. Except as required under applicable securities laws, Callinex does not assume the obligation to update any forward-looking statement.

View original content to download multimedia:http://www.prnewswire.com/news-releases/callinex-intersects-5m-of-8-35-cueq-and-9m-of-3-72-cueq-with-145m-step-out-from-the-rainbow-discovery-in-the-flin-flon-mining-district-mb-301173430.html

SOURCE Callinex Mines Inc.

TSXV: GGI
OTC: GGIFF
Frankfurt: RQM

VANCOUVER, BC, Nov. 16, 2020 /PRNewswire/ – Garibaldi Resources (TSXV: GGI) (the “Company” or “Garibaldi”) is pleased to provide an update on plans to extend its drilling program up at the Eskay Camp. As winter arrives at the E&L nickel-copper-cobalt massive sulphide project on Nickel Mountain, drilling will now pivot to the low elevation (430m) Casper quartz gold vein discovered last fall. Garibaldi owns a 100% interest in over 180 sq. kms of highly prospective claims, in the heart of the Eskay Gold Camp. The E&L and Casper are significant major discoveries made by the Company within their claim group in NW British Columbia.

Garibaldi’s flagship E&L nickel-copper-cobalt project features global top tier nickel grades and tenors within a suite of 11 metals critical in the accelerating demand for EV batteries.  The Casper quartz gold vein discovery has produced consistent excellent results in channel samples (see news release dated September 29, 2020), including visible gold. With drill pads completed at Casper, the program will test the grade and width of gold mineralization at depth. Rising gold prices makes Casper an especially attractive prospect and a high priority gold target.

Together, the advancement of two nearby projects will provide gains in productivity utilizing one shared base camp. As results from this season’s deep target drilling at E&L are analyzed and interpreted, the Casper quartz gold vein adds an exciting new drill target within the Garibaldi claim group. Updates on E&L and Casper will follow.

Flow-Through Financing

Garibaldi is also pleased to announce a non-brokered private placement to raise total gross proceeds of up to $3 million CDN. The Company will issue up to 5 million flow-through share units at 60 cents per unit.

Each flow-through unit is comprised of one flow-through share and one half of a non-transferable share purchase warrant. Each full warrant is exercisable into one common share in the capital of the Company at a price of 75 cents for a period of two years. All units from the private placement are subject to a four month hold period from the date of issue.

The financing may include finder’s fees payable in cash and/or securities and is subject to TSX Venture approval. Proceeds from the flow-through financing will be used to advance the Company’s British Columbia properties.

About Garibaldi

Garibaldi Resources Corp. is an active Canadian-based junior exploration company focused on creating shareholder value through discoveries and strategic development of its assets in some of the most prolific mining regions in British Columbia and Mexico.

We seek safe harbor.

GARIBALDI RESOURCES CORP.

Per: “Steve Regoci”
Steve Regoci, President

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or the accuracy of this release.

View original content:http://www.prnewswire.com/news-releases/garibaldi-to-drill-high-grade-casper-quartz-gold-vein-301173531.html

SOURCE Garibaldi Resources Corp.

LOS ANGELES, Nov. 16, 2020 /PRNewswire/ — PodcastOne, a leading podcast company and a subsidiary of LiveXLive Media (Nasdaq: LIVX), announced today that it has named veteran television marketing executive, Ilana Susnow, as its Head of Marketing and Audience Development.  Susnow, who is based in New York City, will oversee all marketing initiatives for PodcastOne and its numerous podcasts, including top shows such as The Adam Carolla Show, The LadyGang, Pitbull’s From Negative to Positive and Off the Vine from Kaitlyn Bristowe.

In the newly created position within the podcasting giant, Susnow will report directly to PodcastOne’s CEO, Peter Morris.  Her responsibilities will include developing and executing marketing strategy and audience growth for PodcastOne, including launching new shows and managing the lifecycle of all programs in the PodcastOne network. In addition, Susnow will have oversight and management of all paid media marketing campaigns, trade deals, event planning and PR, as well as collaborating with the sales team on integrations and talent relations

“I have known Ilana and admired her acumen and skills for almost 20 years.  Her wealth of knowledge and innovative marketing strategies that capture audiences across all media mediums changes the game for us at PodcastOne.  Her addition to our team increases our ability to reach listeners and potential listeners in ways we haven’t before, further strengthening our position as an industry leader,” said Peter Morris, CEO of PodcastOne.

“As the entertainment landscape continues to evolve and consumers are sourcing their content, podcast listenership is growing by leaps and bounds.  There is unlimited potential in the ways we can seek, capture and engage audiences to spark listener growth and increase ad revenue opportunities.  I am thrilled to bring my expertise to PodcastOne,” said Susnow.

Before joining PodcastOne, Susnow was the Head of Marketing and Integrations for E.W. Scripp’s syndicated talk show, “Pickler and Ben,” executive produced by Faith Hill and Oprah veteran, Lisa Erspamer.  Prior to that, Susnow spent over a decade at NBCUniversal where she last served as the VP of Marketing for the Domestic Television Distribution (DTD) group.  In this role she led the division’s company-wide synergies and spearheaded marketing initiatives for first-run and off-net show launches, as well as several sales teams including the Television and New Media team, US and Canada and the Syndicated Station Sales team.  She also oversaw the affiliate relations team for first-run shows, including “Access Hollywood,” “Steve Harvey,” “Harry” and “The Meredith Vieira Show.”

Previously, Susnow was the Director of Marketing for the DTD group, launching shows including the original syndicated run of “Deal or No Deal” and the off-net run of “30 Rock.” Susnow also held the role of Manager, Marketing and Affiliate Relations at NBC and helped facilitate the launch of a business-to-business website for over 800 local stations as a result of the NBC and Universal Television merger.

Susnow graduated from the UCLA Anderson School of Management with a Master’s Degree in Business Administration and also holds a Bachelors of Arts degree from the University of California, Davis. She currently resides with her husband in Hoboken, New Jersey and is a proud 5-time triathlete.

About PodcastOne
PodcastOne is a leading advertiser-supported podcast company, offering a 360-degree solution for both content creators and advertisers, including content development, brand integration and distribution.  Acquired by LiveXLive Media in 2020, the two entities have subsequently teamed to create a new video podcast (Vodcast) network under the LiveXLive umbrella.  Amassing more than 2.8 billion downloads annually, the network produces 400+ episodes weekly across a stable of hundreds of top podcast programs, including influencer talent like Adam Carolla, Shaquille O’Neal, Steve Austin, Erin Brockovich, Amanda Cerney & Jacqueline Fernandez, Kaitlyn Bristowe, Tip “T.I.” Harris, Armando “Pitbull” Perez, Jordan Harbinger, Spencer and Heidi Pratt, Heather Dubrow, The LadyGang, Dr. Drew, Chael Sonnen and hundreds more. Its shows are distributed across its own platform as well as LiveXLive’s owned-and-operated channels on mobile, mobile web, desktop and SmartTV’s.  PodcastOne is the brainchild of Radio Hall of Famer, Norm Pattiz, also the founder of Network Radio-giant, Westwood One.

About LiveXLive Media, Inc.
Headquartered in Los Angeles, California, LiveXLive Media, Inc. (NASDAQ: LIVX) (the “Company”) (pronounced Live “by” Live) is a global platform for live stream and on-demand audio, video and podcast content in music, comedy, and pop culture. LiveXLive, which has streamed over 1,500 since January 2020, has become a go-to partner for the world’s top artists and celebrity voices as well as music festivals concerts, including Rock in Rio, EDC Las Vegas, and many others. In April 2020, LiveXLive produced its first 48-hour music festival called “Music Lives” with tremendous success as it earned over 50 million views and over 5 billion views for #musiclives on TikTok on 100+ performances. LiveXLive’s library of global events, video-audio podcasts and original shows are also available on Amazon, Apple TV, Roku and Samsung TVs in addition to its own app, destination site and social channels. The Company’s wholly-owned subsidiary, PodcastOne, generates more than 2.1 billion downloads annually across more than 300 podcasts. For more information, visit www.livexlive.com and follow us on Facebook, Instagram, TikTok, Twitter at @livexlive, and YouTube.

Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are “forward-looking statements,” which may often, but not always, be identified by the use of such words as “may,” “might,” “will,” “will likely result,” “would,” “should,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “continue,” “target” or the negative of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including: the Company’s reliance on one key customer for a substantial percentage of its revenue; the Company’s ability to consummate any proposed financing or acquisition and the timing of the closing of such proposed transactions, including the risks that a condition to closing would not be satisfied within the expected timeframe or at all or that the closing of any proposed transaction will not occur; the Company’s ability to continue as a going concern; the Company’s ability to attract, maintain and increase the number of its users and paid subscribers; the Company identifying, acquiring, securing and developing content; the Company’s ability to maintain compliance with certain financial and other covenants; the Company successfully implementing its growth strategy, including relating to its technology platforms and applications; management’s relationships with industry stakeholders; the effects of the global Covid-19 pandemic; changes in economic conditions; competition; risks and uncertainties applicable to the businesses of the Company’s subsidiaries; and other risks, uncertainties and factors including, but not limited to, those described in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2020, filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 26, 2020, Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, filed with the SEC on August 14, 2020, and in the Company’s other filings and submissions with the SEC. These forward-looking statements speak only as of the date hereof and the Company disclaims any obligations to update these statements, except as may be required by law. The Company intends that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.

Media Contacts:

For PodcastOne:
Guttman PR
310.246.4600
[email protected]

For LiveXLive:
The Rose Group
[email protected]
[email protected]

LiveXLive / PodcastOne IR Contact:
310.529.2500
[email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/livexlives-podcastone-nabs-veteran-marketing-executive-ilana-susnow-301173464.html

SOURCE LiveXLive Media, Inc.

SOUTH PLAINFIELD, N.J., Nov. 16, 2020 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of data on two rare diseases, providing new insights on the burden of Aromatic L-Amino acid Decarboxylase deficiency (AADC-d) and Duchenne muscular dystrophy caused by nonsense mutation (nmDMD). The data, presented at the Virtual ISPOR Europe 2020 Conference, further advance the understanding of these rare and devastating childhood genetic disorders, and the need and value of effective treatments. 

“PTC has been working with the rare disease community to better understand the impact of rare diseases on patients and their families for over 20 years,” said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics. “These insights are critical so that the best treatments can be made available to patients. PTC is committed to ensuring patients can access clinically differentiated treatments such as our gene therapy for AADC deficiency which, if approved, promises to become the standard of care.”

AADC-d associated with high and accumulating disease burden, demonstrating the need for access to an effective therapy

AADC-d is an ultra-rare, genetic disorder that causes severe disability, and the need for 24-hour care and high mortality.¹ There is currently no effective disease-modifying therapy approved for patients with AADC-d. PTC-AADC (eladocagene exuparvovec) is the first treatment for AADC-d under regulatory review. The Marketing Authorization Application was submitted to the European Medicines Agency (EMA) in January 2020, and the Committee for Medicinal Products for Human Use (CHMP) opinion is expected in the first half of 2021.

A review of 66 patient case reports found that symptoms of AADC-d that contribute to high disease burden started from birth (in 29 percent of cases) and accumulated over time.² By age 6, 28 percent of patients were so severely disabled that they experienced symptoms in six core domains.*

Further data from 28 patients who had received PTC’s investigational gene therapy, PTC-AADC was presented, including data from three clinical trials with follow-up from one to nine years, predicting the long-term and durable benefits of the therapy,³ including future motor milestone achievement, by using the Peabody Developmental Motor Scales assessment (PDMS-2) score.

New insights into the impact of nmDMD and treatment from patient and carer perspectives^4,5,6

nmDMD is a rare and fatal genetic disorder that results in progressive muscle weakness from early childhood, and leads to premature death in the mid-twenties due to heart and respiratory failure.⁷ PTC provides access to two of the first drugs approved for nmDMD in the world.

This first known qualitative study evaluating real-life patient and caregiver burden showed that nmDMD has a substantial and multi-faceted impact on both patient and caregivers, including physical, emotional, social and time related consequences.^4,5,6 As part of the research, several caregivers reported a positive change in their child’s condition following initiation with Translarna™ (ataluren) and subsequently an improvement in health-related quality of life (HRQoL).^4,5

“These findings reinforce the need for treatments that address the high unmet need in Duchenne muscular dystrophy and the vital spill over benefits that treatments could also provide for families and caregivers. By improving symptoms, reducing loss of function, or delaying disease progression, treatments have the potential to positively impact the health-related quality of life of individuals, families and caregivers living with Duchenne,” said Sarah Acaster, Principal Investigator, Acaster Lloyd Consulting Ltd (ALC).

Overview of PTC data presented at ISPOR EU 2020

About aromatic L-amino acid decarboxylase deficiency (AADC-d)

AADC-d is an ultra-rare, genetic, life-shortening disorder that causes severe disability and ongoing physical and mental suffering from the first few months of life, with many reliant on feeding tubes or breathing support to survive, and life-long, 24-hour care.[8] AADC deficiency leads to delays or failure to reach developmental milestones, such as head control, sitting, standing, walking, or talking, low muscle tone (also known as muscular hypotonia), severe, seizure-like episodes involving involuntary eye movement (also known as oculogyric crises), autonomic abnormalities, and the need for life-long care.⁷ Significant health issues include infections, orthopedic and cardiac complications, and other comorbidities.

About Duchenne Muscular Dystrophy
Primarily affecting males, Duchenne muscular dystrophy (Duchenne) is a rare and fatal genetic disorder that results in progressive muscle weakness from early childhood and leads to premature death in the mid-twenties due to heart and respiratory failure. It is a progressive muscle disorder caused by the lack of functional dystrophin protein. Dystrophin is critical to the structural stability of all muscles, including skeletal, diaphragm, and heart muscles. Patients with Duchenne can lose the ability to walk as early as age ten, followed by loss of the use of their arms. Duchenne patients subsequently experience life-threatening lung complications, requiring the need for ventilation support, and heart complications in their late teens and twenties.

About PTC Therapeutics, Inc.
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.

For More Information:

Investors

Lisa Hayes

+1 (732) 354 8687
[email protected]

Media:

Jane Baj

+1 (908) 912-9167
[email protected]  

Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of regulatory submissions and responses and other matters; expectations with respect to PTC’s gene therapy platform; PTC’s strategy, future operations, future financial position, future revenues and projected costs; and the objectives of management. Other forward-looking statements may be identified by the words “guidance,” “plan,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions.

PTC’s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: expectations with respect to PTC’s gene therapy platform; the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC’s products or product candidates that PTC commercializes or may commercialize in the future; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC’s products and product candidates; PTC’s scientific approach and general development progress; and the factors discussed in the “Risk Factors” section of PTC’s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC’s other filings with the SEC. You are urged to carefully consider all such factors.

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory or prove to be commercially successful, including Translarna, Emflaza or PTC-AADC.

The forward-looking statements contained herein represent PTC’s views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.

* Six symptom domains of AADC deficiency: Developmental delays, movement disorders (e.g. oculogyric crises, muscle spasms), problems with muscle tone (e.g. floppiness), behavior and sleeping problems, autonomic function problems (e.g. problems with the regulation on involuntary body processes such as heart function and temperature control), and cardiovascular/gastrointestinal/endocrine/respiratory problems.

¹ Wassenberg. T, et al. Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency. Orphanet J Rare Dis. 2017;12:12.
² BakidouA, Werner C, Buesch K. Age at onset and frequency of clinical signs and symptoms in patients with AADC deficiency: A systematic literature review. Poster to be presented at the ISPOR Europe Annual Meeting; November 16-19, 2020.
³ Simons C, Sudhapalli P, Buesch K, Bennison C. Estimating the long-term effects of therapy for patientswith aromatic l-amino acid decarboxylase deficiency (AADC-d) using individual participant data. Poster to be presented at the ISPOR Europe Annual Meeting; November 16-19, 2020.
⁴ Williams K, Buesch K, PiglowskaN, Davidson I, RanceM, BoehnkeA, AcasterS. The development of a conceptual model on the impact of caring for an individual with nonsense mutation Duchenne Muscular Dystrophy. Poster to be presented at the ISPOR Europe Annual Meeting; November 16-19, 2020.
⁵ Williams K, Buesch K, PiglowskaN, AcasterS. Symptoms and impacts of nonsense mutation Duchenne Muscular Dystrophy: A qualitative study and the development of a patient-centredconceptual model. Poster to be presented at the ISPOR Europe Annual Meeting; November 16-19, 2020.
⁶ Williams K, Buesch K, Piglowska N, Davison I, Rance M, Boehnke A, Acaster S. Symptoms and impacts of nonsense mutation Duchenne Muscular Dystrophy at different stages of ambulation. Poster to be presented at the ISPOR Europe Annual Meeting; November 16-19, 2020
⁷ Van Riuten H, Bushby K, Guglieri M. State-Of-The-Art Advances in Duchenne Muscular Dystrophy. EMJ. 2017;2[1]:90-99.

View original content:http://www.prnewswire.com/news-releases/ptc-therapeutics-highlights-data-on-high-disease-burden-and-value-of-treatment-across-two-rare-diseases-301173398.html

SOURCE PTC Therapeutics, Inc.

PITTSBURGH, Nov. 16, 2020 /PRNewswire/ — Braskem (B3: BRKM3, BRKM5 and BRKM6; NYSE: BAK; LATIBEX: XBRK), the largest polyolefins producer in the Americas and leading producer of biopolymers in the world, today announced the successful completion of a $10 million investment towards the expansion of the company’s U.S. Innovation and Technology (I&T) Center located in Pittsburgh, Pennsylvania.  The expansion project adds eight new research and development laboratories with state-of-the-art equipment for developing new proprietary technologies to support innovations in Catalysis, Recycling and 3D Printing. 

In accelerating its scientific research capabilities, Braskem is strengthening the development of proprietary technologies as well as continuing to build on client R&D partnership and collaboration programs. The new laboratories directly support the company’s broader sustainability based innovation objectives and its Carbon Neutral Circular Economy goals. The I&T Center facility expansion is focused on catalysis and petrochemical process technology capabilities, expanding its 3D Printing research capabilities, and also contains advanced polymer characterization laboratories, which include chromatography, polymer cracking and microscopy analyses. Overall, the expansion complements the site’s existing research and lab footprint and capabilities.   

Srivatsan Iyer, Braskem Vice President of Strategy, Planning and Innovation & Technology, commented, “The successful completion of our U.S. I&T Center expansion is designed to house the latest, cutting-edge equipment for research, which will allow Braskem to explore new avenues for growth. These new world class laboratories complement the diverse expertise of our I&T team members, and support Braskem’s innovation goals, especially in the critical areas of circular economy, sustainability, recycling as well as additive manufacturing. The Braskem team’s efforts to safely complete this ambitious investment project amid a worldwide pandemic really speaks to the commitment of Braskem towards technology development, and the confidence we have in the future, both as a company and as a client centric, technology innovator.”

Much like Braskem’s I’m green™ bio-based polyethylene (PE), made from responsibly sourced sugarcane, inventing new chemical processes to recycle post-consumer plastic that requires less energy to produce, will help Braskem fulfill its commitment to a future centered around the Carbon Neutral Circular Economy.  Braskem scientists and researchers in Pittsburgh will use the new labs to test new ways to convert a mixed, post-consumer plastics stream back into raw materials that can then be used to produce new plastics that meets the requirements of strictly regulated industries such as automotive, food and healthcare applications.

Gilfranque Leite, Braskem Innovation and Technology Director, stated, “We have a clear value proposition when we make products with a lower carbon footprint or use plastic waste in a circular fashion. Our clients and brand owners have programs focused on these important areas, yet many don’t have the in-house technology capabilities to do this R&D intensive work on their own. In partnering with Braskem, we can directly support them in achieving their sustainability goals, as well as create really exciting and disruptive technologies in our Pittsburgh I&T Center.”

The I&T Center expansion was designed in-line with Braskem’s broader, company-wide, commitment to sustainability. The project used construction blocks containing the Center for Regenerative Design & Collaboration’s (CRDC) RESIN8^TM technology which utilizes a concrete aggregate replacement made from post-consumer plastic waste.  The use of CRDC’s RESIN8 ^TM blocks creates demand for formerly landfill-bound mixed plastics and diverts plastic waste from otherwise escaping waste collection and going back into the environment. Not only do the blocks have additional strength and the same certifications as traditional concrete blocks, but they also weigh less, which helps reduce their carbon impact and lowers the cost of shipping in the transportation process.

Braskem Global Innovation & Technology
Braskem’s U.S. Innovation & Technology Center in Pittsburgh is one of the largest of Braskem’s four global technology centers and is one of America’s leading polymer research centers. Braskem’s Innovation & Technology Center in Pittsburgh has been named as a Top Workplace Award winner for six consecutive years by the Pittsburgh Post-Gazette’s list of Top Workplaces. Of the 299 people who work at Braskem’s Innovation & Technology team around the world, 55 work in Pittsburgh. Braskem’s innovation structure is composed of two Innovation & Technology Centers located in Pittsburgh and Triunfo, Brazil, a Center for Research on Renewable Technologies located in Campinas, São Paulo, Brazil and a Technical Center in Wesseling, Germany.

ABOUT BRASKEM
With a global vision of the future oriented towards people and sustainability, Braskem is committed to contributing to the value chain for strengthening the Circular Economy. The petrochemical company’s almost 8,000 team members dedicate themselves every day to improve people’s lives through sustainable chemicals and plastics solutions. Braskem has an innovative DNA and a comprehensive portfolio of plastic resins and chemical products for diverse segments, such as food packaging, construction, manufacturing, automotive, agribusiness, healthcare and hygiene, among others. With 41 industrial units in Brazil, the United States, Mexico and Germany, and net revenue of R$52.3 billion (US$13.2 billion), Braskem exports its products to clients in more than 100 countries.

Braskem America is an indirect wholly owned subsidiary of Braskem S.A. headquartered in Philadelphia. The company is the leading producer of polypropylene in the United States, with six production plants located in Texas, Pennsylvania and West Virginia, an Innovation and Technology Center in Pittsburgh, and operations in Boston focused on leveraging groundbreaking developments in biotechnology and advanced materials. For more information, visit www.braskem.com/usa.

Braskem on English social media:                                               

www.facebook.com/BraskemGlobal  
www.linkedin.com/company/braskem
www.twitter.com/BraskemSA 

View original content to download multimedia:http://www.prnewswire.com/news-releases/braskem-completes-us-innovation-and-technology-center-expansion-301170231.html

SOURCE Braskem

LISHUI, China, Nov. 16, 2020 /PRNewswire/ — Tantech Holdings Ltd (NASDAQ: TANH) (“Tantech” or the “Company”), a clean energy company in China, today announced the launch by its subsidiary, Shangchi Automobile Co., Ltd. (“Shangchi Automobile”), of two highly innovative driverless and autonomous street sweepers. The Shangchi SC-120A model features unmanned, automatic sweeping, and the Shangchi SC-120B model features manned, autonomous, intelligent sweepingle.

Shangchi Automobile has a long history in vehicle development. The company was founded in 2011, with manufacturing based in Zhangjiagang City, Jiangsu Province. Its innovative driverless and autonomous street sweepers being launched today, were designed for quieter operation and improved cleaning performance, with the ability to reduce or eliminate the 7 to 8 humans required for typical sweeper vehicle operation. Lidar-based, machine vision technology will enable the driverless model to safely and accurately operate in common environments. The sweepers have two primary operating modes, cleaning and litter-collecting, and can be used for 10 hours at a time or until full. The multi-patented vehicles will come with 1 year warranties.

Mr. Wangfeng Yan, Chief Executive Officer of Tantech, said, “The sanitization market is long overdue for major innovation to increase performance and lower operating costs. It is common to find sweepers still using inefficient, suction technology designed 70 or so years ago requiring expensive, heavy power consumption. We are very excited about the potential for both of our new, state-of-the-art models, which are capable of delivering a higher return on investment to the government organizations, cleaning services and businesses that we are targeting. Both vehicles are undergoing pilot programs, with mass production planned for the first half of 2021. Initial sales are expected to be primarily in the domestic China market, followed by international demand in Europe and North America.”

Mr. Yan continued, “The move to develop special use vehicles follows changes in China’s national subsidy policy to encourage usage of new energy vehicles and the application of unmanned operation of special use vehicles. We developed very attractive, feature rich vehicles that integrate information collection technology, data analysis systems, artificial intelligence controls, positioning and navigation systems, automatic actuators, and safety assurance technology. Our innovative street sweepers integrate highly intelligent route learning and memory, and real-time deep learning, in order to facilitate assisted driving or driverless driving.”

About Tantech Holdings Ltd.

Established in 2001 and headquartered in Lishui City, Zhejiang Province, China, Tantech, together with its subsidiaries, is now, in addition to be a developer and manufacturer of bamboo-based charcoal, an innovative leader in the design, manufacture and distribution of electric vehicles. The Company has also invested in mining business in 2018 and 2019.

For more information please visit: http://ir.tantech.cn.

Forward-Looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulations, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by this cautionary statement and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

View original content:http://www.prnewswire.com/news-releases/tantech-subsidiary-launches-innovative-driverless-and-autonomous-street-sweepers-301173457.html

SOURCE Tantech Holdings Ltd.

NANPING, China, Nov. 16, 2020 /PRNewswire/ — Happiness Biotech Group Limited (the “Company” or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, announced today that the Company’s experience stores started offering Coenzyme Q10 – a best-selling product from Xiamen Kingdomway Group Company (“KDW”, SZSE: 002626).

Coenzyme Q10 is a vitamin-like substance that is produced naturally by the human body. Research suggests coenzyme Q10 may help treat or prevent disease ranging from diabetes,migraines to Alzheimer’s disease, as well as slow signs of aging. KDW, founded in 1997, is the world’s largest manufacturer of coenzyme Q10. KDW is currently publicly listed on the Shenzhen Stock Exchange.

“Coenzyme Q10 Capsule is one of the most popular nutrition supplement products in China. At present, we have 26 experience stores all over China and formed a certain scale effect. Adding Coenzyme Q10 Capsule in our product offerings brings greater market influence and sales volume to our experience stores. This is just a beginning of our plan to further diversify our product series and improve the sales performance of the stores,” said Mr. Xuezhu Wang, CEO of the Company.

About Happiness Biotech Group Limited

Headquartered in Nanping, China, Happiness Biotech Group Limited is an innovative China-based nutraceutical and dietary supplements producer focused on the research, development, manufacturing and marketing of a variety of products made from Chinese herbal extracts and other ingredients. The Company’s goal is to provide high-quality products to our consumers. Over the past 14 years, the Company has established a product portfolio consisting of 32 PRC National Medical Products Administration registered “Blue-Cap” SKUs of nutraceutical and dietary supplements products. For more information, please visit: www.happ.org.cn.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following:  the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China, the COVID-19 outbreak and its impact on our operations and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission.  For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

View original content:http://www.prnewswire.com/news-releases/happiness-biotech-starts-offering-kingdomway-coenzyme-q10-in-its-experience-stores-301173452.html

SOURCE Happiness Biotech Group Limited